Clinical Trials · NCT05929066
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 2,335
- Start date
- Jul 2023
- Locations
- 134 sites, 12 countries
- Primary endpoint
- Percent Change From Baseline in Body Weight